His win rate puts Warren Buffett to shame…

Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.

RNAC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 31.20%

Insider Buying (Last 12 Months): $366,519.60

Insider Selling (Last 12 Months): $0.00

Cartesian Therapeutics Insider Trading History Chart

Cartesian Therapeutics Share Price & Price History

^$21.03

▲ +0.13 (0.62%)

As of 04/26/2024 09:53 PM ET

Days: 30 | 90 | 365

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

Cartesian Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Timothy A Springer	Director	Buy	634	$18.00	$11,412.00	1,035,780
3/14/2024	Timothy A Springer	Director	Buy	21,612	$16.20	$350,114.40	1,017,228
3/11/2024	Timothy A Springer	Director	Buy	40	$19.50	$780.00	3,213
3/8/2024	Timothy A Springer	Director	Buy	160	$19.80	$3,168.00	3,173
2/6/2024	Timothy A Springer	Director	Buy	26	$19.50	$507.00	2,933
1/17/2024	Timothy A Springer	Director	Buy	26	$20.70	$538.20	2,907

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

SEC Filings (Institutional Ownership Changes) for Cartesian Therapeutics (NASDAQ:RNAC)

86.95% of Cartesian Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Cartesian Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company	Details
4/23/2024	Hall Laurie J Trustee	52,775	$34K	0.0%	N/A	0.979%

Data available starting January 2016

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $21.03

$20.71

$21.74

50 Day Range

MA: $19.20

$13.12

$23.61

52 Week Range

Now: $21.03

$11.66

$42.60

Volume

123,800 shs

Average Volume

46,227 shs

Market Capitalization

$113.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Who are the company insiders with the largest holdings of Cartesian Therapeutics?: Cartesian Therapeutics' top insider shareholders include:
Timothy A Springer (Director)
Learn More about top insider investors at Cartesian Therapeutics.
Who are the major institutional investors of Cartesian Therapeutics?: Cartesian Therapeutics' top institutional investors include:
Hall Laurie J Trustee — 0.98%
Learn More about top institutional investors of Cartesian Therapeutics stock.
Which major investors are buying Cartesian Therapeutics stock?: In the last quarter, RNAC stock was purchased by institutional investors including:
Hall Laurie J Trustee